Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: A comparative study

Kazerooni, Talieh; Ghaffarpasand, Fariborz; Asadi, Nasrin; Dehkhoda, Zahra; Dehghankhalili, Maryam; Kazerooni, Yasaman

doi:10.1016/j.jcma.2013.01.009

Cited by 44 publications

(27 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A majority of the thrombophilic defects in women with RPL are in the protein C pathway; thus, a decreased protein C activity has been previously reported in these patients . Hyperandrogenaemia, specifically increased DHEAS, has been associated with RPL in PCOS patients . We have reported in previous studies the association of dysregulated T‐cell immunity, such as increased Th1/Th2 cell ratios in women with RPL and RIF when compared to fertile controls .…”

Section: Discussioncontrasting

confidence: 51%

Plasminogen Activator Inhibitor‐1 4G/5G Polymorphism is Associated with Reproductive Failure: Metabolic, Hormonal, and Immune Profiles

Garcia

Sung

Mullenix

et al. 2016

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 51%

Plasminogen Activator Inhibitor‐1 4G/5G Polymorphism is Associated with Reproductive Failure: Metabolic, Hormonal, and Immune Profiles

Garcia

Sung

Mullenix

et al. 2016

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…However, thrombophilic defects sometimes occur, and women with thrombophilic defects are at an increased risk for pregnancy-associated thromboembolism and other vascular complications, such as preeclampsia and fetal loss. 8,9 Human plasminogen activator inhibitor-1 (PAI-1) plays a vital role in hypofibrinolysis and thrombotic complications. 10 The PAI-1 gene consists of nine exons, and several polymorphisms within the PAI-1 gene [including the most investigated promoter variants, a PAI-1-675G/A (4G/5G) insertion-deletion and a -844G/A single nucleotide polymorphism (SNP)] have been reported.…”

Section: Introductionmentioning

confidence: 99%

Association between Plasminogen Activator Inhibitor‐1 Gene Polymorphisms and Recurrent Pregnancy Loss: A Systematic Review and Meta‐Analysis

Chen

Nie

Lü

2014

American J Rep Immunol

View full text Add to dashboard Cite

Human plasminogen activator inhibitor-1 (PAI-1) is closely related to embryonic development and pregnancy success. The association between PAI-1 gene polymorphisms (PAI-1-844G/A and PAI-1-675G/A) and the risk of recurrent pregnancy loss (RPL) is controversial. Therefore, we perform this review to clarify the association between PAI-1 gene polymorphisms and RPL risk. We performed a systematic search for studies that described the effect of PAI-1 polymorphisms on RPL risk. The odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were considered under recessive genetic models. Furthermore, we conducted a subgroup analysis based on the studies' geographic regions of origin. Data were analyzed using Stata 11.2 software. Eighteen studies were included, and a high degree of statistical heterogeneity existed among the studies. In this study, we found a significant association between the PAI-1-675G/A polymorphism and the risk of RPL under the recessive model (OR = 1.70, 95% CI = 1.21-2.38). However, no significant association between the PAI-1-844G/A polymorphism and RPL was noted. PAI-1-675G/A (4G/5G) polymorphisms play a potential role in RPL. The screening of PAI-1 (4G/5G) gene mutations should be included during an RPL diagnostic workup, and patients should be treated using anticoagulant therapy during pregnancy if necessary.

show abstract

“…Kazerooni and coworkers, also observed higher levels of Hcy in patients with RPL than in healthy people. 14 In the present study folic acid was given in an oral daily dose of 5mg/day to women of group 1 and in a dose of 0.5mg/day for women of group 2. We found that the effect of folic acid 5mg/day was significant while the effect of folic acid 0.5 mg was non-significant against the occurrence of early recurrent pregnancy loss (p < 0.05).…”

Section: Discussionmentioning

confidence: 92%

The effect of folic acid in women with recurrent pregnancy loss, polycystic ovary syndrome and hyperhomocysterinemia

Ia¹,

As²,

Tm³

et al. 2018

MOJWH

View full text Add to dashboard Cite

Introduction: Polycystic ovary syndrome (PCOS) is one of the major causes of infertility Worldwide and affects about 20% of infertile couples. Patients with PCOS have an increased risk of first trimester spontaneous abortion ranging from 25% to 73%. Repeated pregnancy loss (RPL), specified as two or more consecutive pregnancy losses before the 20th week of pregnancy is a frequent obstetric complication. In spite of this, 50% of cases the pathophysiology remains unknown Aim of the work: The purpose of this work was to prevent early recurrent pregnancy loss in adult females with polycystic ovary syndrome and hyperhomocysteinemia by using folic acid 5mg/daily. Methods: The current study was carried out on 80 pregnant women in reproductive period, their age ranged from 20 to 35 ages. They were assorted into two groups: group one studying 40 women having a history of RPL with PCOS and group two including 40 adult females having a history of RPL and non PCOS. The women in the two groups were treated with 5mg/day folic acid/day for 20 weeks. Results: Homocysteine level in patients with RPL and polycystic ovary was significantly higher than in women without polycystic ovary syndrome. In addition, folic acid administration at a daily dosage of 5 mg reduced significantly the rate of fetal loss. Conclusion: We found that folic acid supplementation early in pregnancy, in a pharmacological dose might have a beneficial effect on pregnancy outcome.

show abstract

Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: A comparative study

Abstract: Hyperinsulinemia, hyperandrogenemia, hypofibrinolysis, and hyperhomocysteinemia as well as APCR and factor V Leiden mutations are associated with RPL in patients with PCOS.

Cited by 44 publications

References 34 publications

Plasminogen Activator Inhibitor‐1 4G/5G Polymorphism is Associated with Reproductive Failure: Metabolic, Hormonal, and Immune Profiles

Plasminogen Activator Inhibitor‐1 4G/5G Polymorphism is Associated with Reproductive Failure: Metabolic, Hormonal, and Immune Profiles

Association between Plasminogen Activator Inhibitor‐1 Gene Polymorphisms and Recurrent Pregnancy Loss: A Systematic Review and Meta‐Analysis

The effect of folic acid in women with recurrent pregnancy loss, polycystic ovary syndrome and hyperhomocysterinemia

Contact Info

Product

Resources

About